| ²é¿´: 410 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
|
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. in place ÔÚ¾äÖеÄÒâ˼ÊÇʲô£¿ лл£¡ |
» ²ÂÄãϲ»¶
¼±Ðèµ÷¼Á
ÒѾÓÐ9È˻ظ´
É격/¿¼²©
ÒѾÓÐ4È˻ظ´
»¯¹¤Ñ§Ë¶294·Ö£¬Çóµ¼Ê¦ÊÕÁô
ÒѾÓÐ37È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
260Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬320Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ç󲩵¼£üÉúÎïÖÊ»ù¶à¿×̼/³¬¼¶µçÈÝ·½Ïò£¬ÒÑÓÐÏà¹Ø³É¹û£¬Ñ°ÄÜÔ´²ÄÁÏ/̼²ÄÁÏ·½ÏòÀÏʦ
ÒѾÓÐ3È˻ظ´
¶þ±½¼×ͪËáÀàÑÜÉúÎï
ÒѾÓÐ6È˻ظ´
½ÓÊÜÈκε÷¼Á
ÒѾÓÐ4È˻ظ´
weichin
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 183
- Ó¦Öú: 18 (СѧÉú)
- ½ð±Ò: 9734.7
- ºì»¨: 17
- Ìû×Ó: 4116
- ÔÚÏß: 345.2Сʱ
- ³æºÅ: 1490943
- ×¢²á: 2011-11-14
- רҵ: ½á¹¹ÌÕ´É

2Â¥2012-03-23 15:32:17
natisean
½ð³æ (СÓÐÃûÆø)
- ·ÒëEPI: 4
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 1047.1
- ºì»¨: 23
- Ìû×Ó: 104
- ÔÚÏß: 18.9Сʱ
- ³æºÅ: 1261244
- ×¢²á: 2011-04-10
- רҵ: ¾ÛºÏÎï¹²»ìÓ븴ºÏ²ÄÁÏ
3Â¥2012-03-23 16:19:59













»Ø¸´´ËÂ¥
20